Please login to the form below

Not currently logged in
Email:
Password:

BMS to buy Amira Pharmaceuticals

Bristol-Myers Squibb is to purchase inflammatory and fibrotic disease specialists Amira Pharmaceuticals in an acquisition potentially worth $475m

Bristol-Myers Squibb (BMS) is to purchase inflammatory and fibrotic disease specialists Amira Pharmaceuticals in an acquisition potentially worth $475m.

California-based Amira will receive $325m in upfront payments, with additional milestones totalling $150m.

Once the deal is complete, BMS will have access to Amira's fibrosis programme, including the investigative drug AM152, which is about to enter phase II clinical development.

Amira also has a preclinical programme for autotoxin – an enzyme associated with tumours.

BMS said it will retain Amira's scientists working on these projects.

Elliott Sigal, executive vice president, chief scientific officer and president, Research and Development at BMS, described fibrotic diseases as an area of "high unmet medical need." The Amira acquisition part of the company's plans to diversify its pipeline, he added.

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics